How well does Malaysia achieve value for money in public sector purchasing of medicines? Evidence from medicines procurement prices from 2010 to 2014

Abstract

Background: Malaysia's public healthcare sector provides a greater volume of medicines at lower overall cost compared to the private sector, indicating its importance in providing access to medicines for Malaysians. However, the Ministry of Health (MOH) has concerns about the continuous increase in the public sector medicines budget, and achieving efficiencies in medicines procurement is an important goal. The objectives of this study were to assess the overall trend in public sector pharmaceutical procurement efficiency from 2010 to 2014, and determine if the three different ways in which MOH procures medicines influence efficiency. Methods: We matched medicines from the public sector procurement report by medicine formulation to medicines with a Management Sciences for Health (MSH) International Reference Price (IRP) for each year. Price ratios were calculated, and utilizing the information on quantity and expenditure for each product, summary measures of procurement efficiency were reported as quantity-and expenditure-weighted average price ratios (WAPRs) for each year. Utilizing MOH procurement data to obtain information on procurement type, a multiple regression analysis, controlling for factors that can influence prices, assessed whether procured efficiency (relative to IRPs) differed by MOH procurement type. Results: Malaysia's public sector purchased medicines at two to three times the IRP throughout the study period. However, procurement prices were relatively stable in terms of WAPRs each year (2.2 and 3.2 in 2010 to 1.9 and 2.9 in 2014 for quantity and expenditure WAPRs, respectively). Procurement efficiency did not vary between the three different methods of MOH procurement. Procurement efficiency of both imported originators and imported generics were significantly lower (P < 0.001 and P < 0.01) than local generic products, and medicine source and category influenced the procurement efficiency of each MOH procurement mechanism. Conclusion: The design of different medicines procurement mechanisms, along with the balance between ensuring competitive procurement prices and adhering to national industry and procurement policies, have not been able to achieve lower public sector medicines procurement prices (relative to IRP). Introducing pooled procurement options along with continuous monitoring of procurement efficiency and exploring ways to improve price competition among local and foreign suppliers is recommended.

How Well Does a Sequential Minimal Optimization Model Perform in Predicting Medicine Prices for Procurement System?

“…Policymakers in many countries are currently considering and discussing a range of approaches intended to reduce drug prices and enhance the best options in the pharmaceutical marketplace. Pharmaceutical procurement data over time contribute useful insights when evaluating the need for new approaches and planning the policies [ 41 ]. However, measuring the change of the price for each medicine could be difficult because the market for pharmaceuticals is inefficient and complex [ 42 ].…”

Public Procurement, Big Data Analytics Capabilities, and Healthcare Supply Chain Sustainability

“…The study utilized machine learning modes to predict inefficiencies in public procurement and found net positive impacts. Another study based on Malaysian's public sector health care procurement revealed that the country's public health sector purchased different medicines two to three times the international reference price (IRP) [46]. This study concluded that exiting procurement mechanisms failed to achieve value for money medicine sourcing by balancing ensuring competitive procurement prices and adherence to national procurement policies.…”

The Implementation of Needle Syringe Exchange Program in Malaysia: A Short Communication

“…The government allocates huge amounts of money to buy drugs from pharmaceutical companies but, in return, needs to disperse the medicine free-of-charge to the populace. In 2016, the government expenditures on medicines for public hospitals reached MYR 2.1 billion, which accounted for approximately 37% of the overall public health sector expenditure (Hamzah et al, 2020).…”